B+
Bull case
20%
Probability
Target price
$2.97
-68.0% vs current
FDMT
4D Molecular TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$1.98
-78.6% vs current
B-
Bear case
20%
Probability
Target price
$0.50
-94.6% vs current
AI sentiment snapshot
Latest data as of 2025-11-24
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Investor focus is binary: positive readouts or partnership news could trigger strong rallies, while cash‑runway or negative clinical headlines drive rapid downside. Filings and recent investor releases emphasize active programs and continued R&D spend, keeping near‑term sentiment cautious and event‑driven.
RankAlpha Sentiment AI - 2025-11-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventClinical readouts for lead AAV programsHigh impact
Upcoming early‑stage trial readouts or cohort updates that would materially re‑rate the stock on positive efficacy/safety signals (company Q3 2024 results and investor release).
-catalystFinancing / dilution riskHigh impact
Ongoing R&D spend implies a meaningful chance of near‑term financing; equity raises would be dilutive and pressure the share price.
-catalystPlatform validation via partnership/licensingHigh impact
A material licensing or partnership agreement for the capsid/platform would de‑risk programs and likely produce multi‑quarter valuation upside.
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-24 • Updated nightlySource: Internal modelMethodology